← boardnext 2026-10-30
INBX
Inhibrx Biosciences, Incdistress 3/10 · well-funded / low risk$84.00-2%today-41% from 52w high
Oncology 1
Lead: chondrosarcoma
Revenue
pre-revenue
Liquidity
$162M
Runway
1.2 yrs
Shares 1y
+1%
Price & events
+5.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.2%
1D
-5.7%
1W
-9.6%
1M
-30.0%
3M
+12.5%
6M
+262.1%
1Y
+489.5%
2Y
—
5Y
+571.6%
All
Overview
- Market Cap
- $1.23B
- Enterprise Value
- $1.25B
- Volume
- 8.07K
- 52 Week Range
- $20.93 – $142
- Total Shares
- 14.67M
- Float Shares
- 8.37M
- Short %
- 31.40%
- % Held by Insiders
- 23.16%
- % Held by Institutions
- 82.24%
- RVOL
- 0.02x
- Beta
- 3.43
Pipeline stages · 1 programs
INBRX-106, Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10-30 Estimated 50% readout ~2026-12-14 | Phase 1/2 | INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg | Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma | — | active not recruiting |
| 2028-12 Estimated 50% readout ~2028-12-31 | Phase 1 | INBRX-109, Irinotecan, Temozolomide | Ewing Sarcoma, Colorectal Adenocarcinoma | — | recruiting |
| 2029-05 Estimated 50% readout ~2029-07-15 | Phase 2/3 | INBRX-106, Pembrolizumab | Head and Neck Squamous Cell Carcinoma (HNSCC) | — | active not recruiting |
| 2025-09-30 | Phase 2 | INBRX-109 | Conventional Chondrosarcoma | 206 | active not recruiting |
Catalyst news & presentations · 14
- expected to begin in 2027Guided 40%trial initiationsecondaryINBRX-106 · Expansion into front-line metastatic NSCLCSEC 8-K
- April 14, 2027Confirmed 100%PDUFAPDUFAozekibart (INBRX-109) · PDUFA goal dateSEC 8-K
- fourth quarter of 2026Guided 70%readoutPhase 2INBRX-106 · PFS data from Phase 2 HexAgon studySEC 8-K
- third quarter of 2026Guided 70%trial initiationsecondaryPhase 3INBRX-106 · Begin Phase 3 portion of HexAgon studySEC 8-K
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
- second quarter of 2026regulatory submissionFiled (NDA/BLA)ozekibart · Plans to submit BLA to FDA in Q2 2026.SEC 8-K
- second quarter of 2026enrollment completesecondaryPhase 1/2ozekibart · Expects to complete enrollment in trial with irinotecan/temozolomideSEC 8-K
- later this quartertrial initiationsecondaryINBRX-106 · Initiate study in perioperative NSCLCSEC 8-K
- second quarter of 2026readoutPhase 1/2ozekibart · PFS data expected to be mature; plan to provide updateSEC 8-K
- June 15, 2026filing acceptanceFiled (NDA/BLA)ozekibart (INBRX-109) · FDA accepted BLA filingSEC 8-K
- first quarter of 2026enrollment completesecondaryPhase 2INBRX-106 · Expects to complete enrollment in Phase 2 portion of Phase 2/3 trial for first-line HNSCCSEC 8-K
- November 14, 2025conferencedata presentationsecondaryozekibart · Detailed results to be presented at CTOS Annual Meeting.SEC 8-K
- 2025-10-23safety signalozekibart · One hepatotoxicity-related fatal event prior to mitigation; risk managed thereafter.SEC 8-K
- third quarter of 2025readoutPhase 1ozekibart · Expansion cohort data readout in up to 50 patientsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-04-08StifelBuy
- 2025-08-22JMP SecuritiesMarket Perform
- 2025-05-15JMP SecuritiesMarket Perform
- 2025-03-18Citizens Capital MarketsMarket Perform
- 2025-01-22JMP SecuritiesMarket Perform
- 2024-07-23JMP SecuritiesMarket Perform
Competitors — chondrosarcoma
- none identified
Recent news
- 2026-07-17Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act (NASDAQ:INBX) - Seeking Alpha
- 2026-07-17Inhibrx Biosciences expands Oxford Finance loan facility to USD 500 million - Bitget
- 2026-07-17Inhibrx Biosciences Secures $500 Million Credit Facility with Oxford Finance to Accelerate Clinical Pipeline Expansion - Minichart
- 2026-07-16Inhibrx Biosciences Expands Oxford Credit Facility to $500 Million, Draws $100 Million, Issues Warrants - TradingView
- 2026-07-16Inhibrx Biosciences (Nasdaq: INBX) secures up to $500M Oxford credit - Stock Titan
- 2026-07-16Inhibrx expands credit facility to $500 million with Oxford - Investing.com
- 2026-07-16Press Release: Inhibrx Announces Amended Loan Agreement With Oxford Finance, Expanding Total Facility to $500.0 Million - Moomoo
- 2026-07-16Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million - PR Newswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.